Fanotaprim

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis[1].

Product Specifications

CAS Number

[2120282-75-7]

Product Name Alternative

VYR-006

UNSPSC

12352005

Target

Antifolate

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/fanotaprim.html

Purity

98.89

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC1=NC=C(N2CCN(C3=CC=CC(C4=CN=C(OC)N=C4)=C3)CC2)C(N)=N1

Molecular Formula

C19H22N8O

Molecular Weight

378.43

References & Citations

[1]Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019;62 (3) :1562-1576.